Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2022
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for NeuroblastomaVandana Batra, Minu Samanta, Mehran Makvandi, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targetsNathan M Kendsersky, Michal Odrobina, Nathaniel W Mabe, et al.
Neuro-Oncology|January 18, 2025
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targetsNathan M Kendsersky, Michal Odrobina, Nathaniel W Mabe, et al.
Pediatric Blood & Cancer|April 21, 2020
Limited antitumor activity of combined BET and MEK inhibition in neuroblastomaJason R Healy, Lori S Hart, Alexander L Shazad, et al.
Cancer Research Communications|November 16, 2022
Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastomaKateryna Krytska, Colleen E Casey, Jennifer Pogoriler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2016
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaLori S Hart, JulieAnn Rader, Pichai Raman, et al.
Nature Communications|August 20, 2024
CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastomaGuillem Pascual-Pasto, Brendan McIntyre, Margaret G Hines, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2021
The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor ModelsNathan M Kendsersky, Jarrett Lindsay, E Anders Kolb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORSEdward Favours, Haiying Tang, Peyton Wong, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastomaAmber K Weiner, Alexander B Radaoui, Matthew Tsang, et al.
Pageof 4